Tag Archives: Early Diagnosis of Alzheimer’s Disease

Blood Test Able to Predict Alzheimer’s Disease Decades Before Symptoms? (BBC News / Neurology)

Posted on August 3, 2019 by Dementia and Elderly Care News

Summary Research published in the Neurology journal claims a significant breakthrough in the development of a blood test (for plasma Aβ42/Aβ40) which may be able to predict Alzheimer’s Disease onset with 94% accuracy. Due caution: “But it’s important to note … Continue reading →

Posted in BBC News, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Quick Insights, Universal Interest | Tagged Alzheimer's Disease: Diagnosis, Alzheimer’s Early Screening, Amyloid, Amyloid and Tau PET, Amyloid Beta, Amyloid Beta (Aβ42 and Aβ40), Amyloid Beta Protein, Amyloid-β (Aβ), Amyloid-β Protein, BBC Health News, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood Proteins as Biomarkers of Disease Research, Blood Test for Brain Amyloidosis: Validated Using Amyloid PET and CSF p-tau181/Aβ42 as Reference Standards, Blood Tests, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, Brain Imaging, Brain Research, Case Finding, Conversion to Dementia From Prodromal Disease, Dementia Diagnosis, Dementia Innovation, Dementia Research, Dementia Screening, Department of Neurology: Washington University, Diagnosis, Diagnosis of Alzheimer's Disease, Diagnostic Imaging, Division of Biostatistics: Washington University, Drug Development for Alzheimer's Disease, Early Detection of Preclinical Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Hope Center for Neurological Disorders: Washington University, Knight Alzheimer's Disease Research Center: Washington University, Mallinckrodt Institute of Radiology: Washington University, Neurology (Journal), Non-Invasive Biomarkers, Plasma Biomarkers, Plasma β-Amyloid 42/40, Plasma Protein Markers of MRI Measures in Asymptomatic Individuals, Preclinical Alzheimer's Disease, Preclinical Biomarkers in Alzheimer's Disease, Predictive Ability (of Tests), Prodromal Alzheimer's Disease, Protein-Based Biomarkers in Blood May Deliver Accurate Diagnoses, Rapid Screening, Recruitment Onto Dementia Clinical Trials, SAP (Protein), SAP: Serum Amyloid Protein, Screening, Screening for Dementia, Washington University School of Medicine | Leave a comment

Dementia Biomarkers Re-Explored? (General Psychiatry / JGCR)

Posted on June 17, 2019 by Dementia and Elderly Care News

Summary A recent systematic review examines biomarkers, as strictly defined, for neurodegenerative diseases. “Vast improvements in neuroimaging techniques have led to newly discovered biomarkers and diagnostics”. p.5 Behavioural biomarkers are mentioned hardly at all. Full Text Link Reference Maclin, JMA. … Continue reading →

Posted in Alzheimer’s Research UK, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Mental Health, Personalisation, Quick Insights, Systematic Reviews, UK, Universal Interest | Tagged 18F-florbetaben, 18F-flutemetamol, 18Fflorbetapir, Alzheimer's Disease: Diagnosis, Alzheimer’s Disease, Alzheimer’s Disease and Dementia, Alzheimer’s Disease Biomarkers, Alzheimer’s Research UK (ARUK), Amyloid and Tau PET, APOE e4 (Apolipoprotein E e4), Apolipoprotein E (APOE) e4 Allele, Behavioural Biomarkers, Beta-Amyloid PET Imaging, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Canonical Syndromes of Primary Progressive Aphasia: Non-Fluent / Agrammatic Variant (nfvPPA), Canonical Syndromes of Primary Progressive Aphasia: Semantic Variant (svPPA), Carbon-11 Pittsburgh Compound-B (C-PIB) Radioisotope Tracer, Cerebral Metabolic Rate for Glucose (CMRgl), Cerebrospinal Fluid (CSF) Biomarkers, Cerebrospinal Fluid and Serum MHPG, CMRgl Decline, Corticobasal Degeneration (CBD), CSF 3-methoxy-4-hydrox-yphenylglycol (MHPG), Dementia With Lewy Bodies (DLB), Differential Diagnosis, DLB: Dementia with Lewy Bodies, Docosahexaenoic Acid (DHA), Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Eicosapentaenoic Acid (EPA), Frontotemporal Dementia (FTD), α-Synuclein, Journal of Geriatric Care and Research (JGCR), Lewy Body Dementia (LBD), Magnetic Resonance Imaging (MRI), Medial Temporal Lobe Atrophy (MTA), Medial Temporal Lobes (MTL), Metabolic Syndrome (MetS), MRI Brain Imaging, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neuroimaging, Neuroimaging in Dementia Diagnosis, Non-Invasive Biomarkers, Pick’s Disease (Frontotemporal Dementia), Positron Emission Tomography (PET), Preclinical Alzheimer's Disease, Primary Progressive Aphasia (PPA), Progressive Supranuclear Palsy (PSP), Rapid Screening, Screening for Dementia, Sea Hero Quest (SHQ) Game, Sea Hero Quest VR, Tau PET, Timely Diagnosis, VaD: Vascular Dementia, Variants of Primary Progressive Aphasia (PPA), Vascular Dementia, [18F]THK5351 | Leave a comment

Eye Tests for Early Detection of Alzheimer’s Disease? (NHS Digital / Ophthalmology Retina)

Posted on March 20, 2019 by Dementia and Elderly Care News

Summary Further discussion about the possibilities of using inexpensive eye tests to detect Alzheimer’s Disease, perhaps years before symptoms appear. This particular technique involves the examination of blood vessels and blood flow in the retina, as detected by Octa (Optical … Continue reading →

Posted in Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Quick Insights, Universal Interest | Tagged Alzheimer's Disease: Diagnosis, Alzheimer’s Disease, Alzheimer’s Disease and Dementia, Alzheimer’s Disease Biomarkers, Assessment and Diagnosis, Bazian, Behind the Headlines, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Central Subfield Thickness (CST), Cognitive Impairment, Critical Appraisals, Dementia Case Finding, Dementia Diagnosis, Dementia Screening, Diagnosis, Diagnosis of Alzheimer's Disease, Diagnostics, Duke University in North Carolina, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Treatment Diabetic Retinopathy Study, Eye Examinations, Foveal Avascular Zone (FAZ) Area, Karen L. Wrenn Alzheimer's Disease Award, Macular Ganglion Cell-Inner Plexiform Layer (GC-IPL), MCI: Mild Cognitive Impairment, Mild Cognitive Impairment, National Institutes of Health, National Institutes of Health (NIH), National Institutes of Health (US), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, NHS Digital (Formerly NHS Choices), Non-Invasive Biomarkers, Octa: Optical Coherence Tomography Angiography, Ophthalmology Retina, Optical Coherence Tomography, Optical Coherence Tomography Angiography (OCTA), Preclinical Alzheimer's Disease, Rapid Screening, Research to Prevent Blindness Inc. (New York), Retina as Early Biomarker of Neurodegeneration, Retinal Biomarkers, Retinal Examination in Neurodegenerative Diseases, Retinal Microvascular and Neurodegenerative Changes in Alzheimer’s Disease, Retinal Microvascular and Neurodegenerative Changes in Mild Cognitive Impairment, Retinal Vessel Density (VD), Screening, Screening for Dementia, Timely Diagnosis, US National Institutes of Health (NIH), USA | Leave a comment

More on Possible Blood Tests for Pre-Symptomatic Alzheimer’s Disease (NHS Digital / Nature Medicine)

Posted on January 28, 2019 by Dementia and Elderly Care News

Summary People with a rare hereditary form of Alzheimer’s Disease (Dominantly Inherited Alzheimer’s Disease) have raised levels of a protein called neurofilament light chain (NfC) in their blood, arising from damage to previously healthy nerve cells. These elevated levels of … Continue reading →

Posted in Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Quick Insights, Universal Interest | Tagged APP or PSEN Mutations, Australia, Basel, Bazian, Behind the Headlines, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood Proteins as Biomarkers of Disease Research, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, Columbia University Medical Center, Dementia Research Centre, Dementia Research Centre: University College London, Department of Biomedical Sciences: Macquarie University, Department of Cellular Neurology: Hertie Institute for Clinical Brain Research, Department of Neurodegeneration: Queen Square Institute of Neurology, Department of Neurology: Columbia University Medical Center, Department of Neurology: Keck School of Medicine at USC, Department of Neurology: Ludwig-Maximilians-Universität München, Department of Neurology: Massachusetts General Hospital, Department of Neurology: Mayo Clinic Jacksonville, Department of Neurology: Washington University School of Medicine, Department of Neuroscience: Icahn School of Medicine at Mount Sinai, Department of Psychiatry and Psychotherapy: University of Tübingen, Department of Radiology: Washington University School of Medicine, Departments of Medicine Biomedicine and Clinical Research: University Hospital Basel, Division of Biostatistics: Washington University School of Medicine, Dominantly Inherited Alzheimer Network, Dominantly Inherited Alzheimer Network (DIAN), Dominantly Inherited Alzheimer's Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Edith Cowan University: Western Australia, Florey Institute of Neuroscience and Mental Health: University of Melbourne, German Center for Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE), Germany, Harvard Medical School, Hereditary Alzheimer's Disease, Hertie Institute for Clinical Brain Research, Icahn School of Medicine at Mount Sinai (New York), Indiana Alzheimer Disease Center and Department of Pathology and Laboratory Medicine: Indiana University School of Medicine, Indiana University School of Medicine, Ludwig-Maximilians-Universität München, Macquarie University, Macquarie University (New South Wales), Massachusetts General Hospital, National Institute on Aging, National Institute on Aging (NIA), National Institute on Aging (US), Nature Medicine, Neurodegeneration Division: The Florey Institute of Neuroscience and Mental Health, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurofilament Light Chain (NfC), Neurofilament Light Chain (NFL), Neurofilament Light Protein (NF-L), Neurofilament Light Protein in Blood: Potential Biomarker of Neurodegeneration, Neurologic Clinic and Policlinic: University Hospital Basel, Neuroscience Research Australia, Non-Invasive Biomarkers, Plasma Biomarkers, Preclinical Alzheimer's Disease, Preclinical Biomarkers and Dementia, Preclinical Biomarkers in Alzheimer's Disease, Protein-Based Biomarkers in Blood May Deliver Accurate Diagnoses, School of Medical Health and Sciences: Edith Cowan University, School of Medical Sciences: University of New South Wales, Serum Neurofilament Light Chain Protein, Switzerland, Taub Institute for Research on Alzheimer's Disease and the Aging Brain: Columbia University Medical Center, United States, University College London, University Hospital Basel, University of Basel, University of Melbourne, University of New South Wales, University of Tübingen, US National Institute on Aging, USA, Warren Alpert Medical School of Brown University, Washington University School of Medicine | Leave a comment

Earlier Diagnosis of Alzheimer’s Disease Using Saliva Test? (NHS Choices / JAD)

Posted on May 25, 2017 by Dementia and Elderly Care News

Summary Pilot research indicates that a chemical in the saliva can be used to differentiate, with relatively high accuracy, between persons who are currently healthy, those with mild cognitive impairment (MCI), and others with Alzheimer’s Disease. Potentially, salivary biomarkers could … Continue reading →

Posted in Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Quick Insights, Universal Interest | Tagged 1H NMR-Based Metabolomics, Alzheimer’s Disease Biomarkers, Alzheimer’s Early Screening, Beaumont Health, Beaumont Research Institute: Beaumont Health, Behind the Headlines, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Canada, Dementia Saliva Testing (Pilot Study), Dementia Screening, Departments of Biological and Computing Sciences: University of Alberta, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Diagnosis of Alzheimer’s Disease Using Saliva, Fred A. and Barbara M. Erb Family Foundation, JAD, Journal of Alzheimer's Disease, MCI: Mild Cognitive Impairment, Metabolomics, Mild Cognitive Impairment (MCI), NHS Digital (Previously NHS Choices), Non-Invasive Biomarkers, Nuclear Magnetic Resonance Spectroscopy (NMR), Oakland University, Potential for Metabolomics and Saliva in Early Diagnosis of Alzheimer’s Disease, Preclinical Biomarkers and Dementia, Preclinical Biomarkers in Alzheimer's Disease, Saliva, Saliva Tests, Salivary Biomarkers, Screening, Screening for Dementia, Screening Tests, Surrogate Biomarkers of Neurodegeneration, United States, University of Alberta, USA, William Beaumont School of Medicine: Oakland University | Leave a comment

Earlier Diagnosis of Glaucoma – and Possibly Many Neurodegenerative Diseases – By Retinal Examination? (BBC News / NHS Choices / Brain)

Posted on May 1, 2017 by Dementia and Elderly Care News

Summary A fluorescent dye injected into the bloodstream may, in future, provide a convenient method of detecting glaucoma earlier – perhaps a decade before more overt symptoms and damage have had the opportunity to develop – by identifying changes in … Continue reading →

Posted in BBC News, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, NHS Digital (Previously NHS Choices), Parkinson's Disease, Quick Insights, UK, Universal Interest | Tagged Annexin 5 Labelled With Fluorescent Dye DY-776 (ANX776), ANX776 Pharmacokinetics and Pharmacodynamics, ANX776-Positive Fluorescent Cells, Apoptosis, Apoptotic Cells in Neurodegenerative Diseases, Apoptotic Neural Cell Death, Assessment and Diagnosis, BBC Health News, Behind the Headlines, Bethan Hughes: Wellcome Trust, Brain (Journal), Centre for Medical Image Computing: University College London, DARC: Detection of Apoptosing Retinal Cells, Dementia Diagnosis, Department of Visual Neuroscience: UCL Institute of Ophthalmology, Detection of Apoptosing Retinal Cells (DARC), Diagnostic Imaging, Diagnostic Markers, Diagnostic Testing, Drusen (Spots on Retina), Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Diagnosis of Parkinson’s Disease, Eye Cells, Eye Examinations, Glaucoma, Glaucoma and Retinal Neurodegeneration Group: UCL Institute of Ophthalmology, Glaucomatous Neurodegeneration, Imperial College London, Imperial College Ophthalmic Research Group (ICORG), Intravenous ANX776, Levels of Apoptosis (DARC Count), London, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neuronal Cell Apoptosis in Patients With Glaucoma, Neuronal Loss, Ocular Neurodegenerative Conditions, Potential of DARC as Surrogate Biomarker. Retinal Ganglion Cell Apoptosis, Retinal Assessments Using DARC (Detection of Apoptosing Retinal Cells), Retinal Cell Apoptosis, Retinal Ganglion Cell Layer, Retinal Nerve Fibre Layer (RNFL), Timely Diagnosis, Translational Imaging Group: University College London, UCL Institute of Ophthalmology, University College London, Western Eye Hospital, Western Eye Hospital: Imperial College Healthcare NHS Trust, Western Eye Hospital: Imperial College Healthcare NHS Trust (ICHNT) | Leave a comment

Under-Diagnosis of Dementia in the Community: an International Review (BMJ Open / JGCR)

Posted on February 8, 2017 by Dementia and Elderly Care News

Summary A literature review and meta-analysis of 23 international studies on the under-detection (i.e. the failure to achieve a diagnosis) of dementia identified a pooled rate of undetected dementia assessed to be 61.7%. The rate of under-detection was higher in … Continue reading →

Posted in Acute Hospitals, Community Care, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), International, Models of Dementia Care, Quick Insights, Royal Wolverhampton NHS Trust, Royal Wolverhampton NHS Trust Authorial Affiliation, Statistics, UK, Universal Interest, Wolverhampton | Tagged Academic Institute of Medicine: University of Wolverhampton, Affluence and Health Inequalities, Age and Gender Differences in Diagnosis Rates, Agewell Foundation (India), Anhui Medical University, Assessment and Diagnosis, Australia, Australian National University, Barriers to Early Diagnosis, BMJ Open, BMJ Publishing Group Ltd, Case Finding, Case Finding for Patients with Dementia, Centre for Research on Ageing Health and Wellbeing: Australian National University, China, Cognitive Assessment Tools, Cognitive Impairment, Dementia Case Finding, Dementia Case Finding Scheme, Dementia Challenge, Dementia Collaborative Research Centre-Early Diagnosis and Prevention: Australian National University, Dementia Diagnosis, Dementia Screening, Dementia Screening Debate, Department of Practice and Policy: University College London, Department of Psychiatry: University of Liverpool, Department of Public Health: Wolverhampton City Council, Diagnosis and Referral, Diagnosis and Support, Diagnosis at Primary Care Level, Diagnosis Gap, Diagnosis of Dementia, Diagnosis Rates, Dignity Foundation (India), Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Screening, Effectiveness of Early Detection and Treatment, Ethical Considerations, Ethical Dilemmas, Ethical Issues of Dementia Care, Ethics and Decision-Making, Europe, Faculty of Education Health and Wellbeing: University of Wolverhampton, General Practice, Geriatric Care and Research Organisation (GeriCaRe), GPs, Health Inequalities, HelpAge India, India, Journal of Geriatric Care and Research (JGCR), Liverpool, Mental Health Inequalities, Mini Mental State Examination (MMSE), National Programme for the Health Care of the Elderly (NPHCE), New Cross Hospital: Royal Wolverhampton NHS Trust, North America, Post Graduate Academic Institute of Medicine: University of Wolverhampton, Reducing Health Inequalities, Research School of Population Health: Australian National University, Royal Wolverhampton NHS Trust, School of Health Administration: Anhui Medical University, Screening, Screening for Cognitive Impairment, Screening for Cognitive Impairment in Older Adults, Screening for Dementia, Screening Programmes, Screening Tests, Socio-Economic Differences in Diagnosis Rates, Timely Diagnosis, UK National Screening Committee (UK NSC), Under-Detection of Dementia, University College London, University of Liverpool, University of Wolverhampton, Wolverhampton City Council | 1 Comment

Tag Archives: Early Diagnosis of Alzheimer’s Disease

Blood Test Able to Predict Alzheimer’s Disease Decades Before Symptoms? (BBC News / Neurology)

Dementia Biomarkers Re-Explored? (General Psychiatry / JGCR)

Eye Tests for Early Detection of Alzheimer’s Disease? (NHS Digital / Ophthalmology Retina)

More on Possible Blood Tests for Pre-Symptomatic Alzheimer’s Disease (NHS Digital / Nature Medicine)

Earlier Diagnosis of Alzheimer’s Disease Using Saliva Test? (NHS Choices / JAD)

Earlier Diagnosis of Glaucoma – and Possibly Many Neurodegenerative Diseases – By Retinal Examination? (BBC News / NHS Choices / Brain)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites